Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER_GOV 1NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 4Lymphoma 3Uterine Cervical Neoplasms 2Small Cell Lung Carcinoma 2Rectal Neoplasms 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Lung Neoplasms 2Colonic Neoplasms 2Burkitt Lymphoma 2Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Recurrence 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Nose Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Metastatic Solid Tumors 1Lymphoproliferative Disorders 1Lymphomatoid Granulomatosis 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Follicular 1Liver Neoplasms 1Hematologic Neoplasms 1Gastrointestinal Neoplasms 1Esthesioneuroblastoma, Olfactory 1Esophageal Neoplasms 1Epstein-Barr Virus Infections 1

Interventions

Peripheral Blood Stem Cell Transplantation 5fludarabine phosphate 4Radiotherapy 4Antilymphocyte Serum 4Vincristine 3Vinblastine 3Procarbazine 3Prednisolone 3Methylprednisolone 3Melphalan 3Filgrastim 3Doxorubicin 3Cyclophosphamide 3Chlorambucil 3Busulfan 3Bortezomib 3Bevacizumab 3tipifarnib 2Vorinostat 2Sorafenib 2Oxaliplatin 2Mycophenolic Acid 2Methotrexate 2Ifosfamide 2Granulocyte Colony-Stimulating Factor 2Etoposide 2Dacarbazine 2Cyclosporine 2Bleomycin 2Biopsy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Recurrence × Tomography, X-Ray Computed × Clear all
NCT06865677 2026-01-21

Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
2 enrolled 7 charts

Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡